Surfactant Replacement Therapy for Meconium Aspiration Syndrome

¹ Department of Pediatrics, Martin Luther King, Jr Hospital/Charles R. Drew University of Medicine and Science, and the University of California Los Angeles School of Medicine

Objective. The pathophysiology of meconium aspiration syndrome (MAS) is related not only to mechanical obstruction of the airways and chemical injury to the respiratory epithelium but also to surfactant inactivation by meconium. A randomized, controlled study was performed to determine whether high-dose surfactant therapy improves the pulmonary morbidity of term infants ventilated for MAS.

Methods. Forty term infants receiving mechanical ventilation for MAS were enrolled in this trial, in which the infants in the study group (n = 20) received up to four doses of 150 mg (6 mL)/kg beractant (Survanta), instilled every 6 hours by continuous infusion for 20 minutes via a side hole endotracheal tube adapter, and the infants in the control group (n = 20) received 6 mL/kg air placebo.

Results. Mean arterial-to-alveolar Po₂ ratio values increased from 0.09 to 0.11 at 1 and 6 hours with a concomitant slight decrease in oxygenation index values from 23.7 to 19.7 at 1 hour and 20.7 at 6 hours after the first dose of surfactant. Oxygenation improved cumulatively after the second and third dose of surfactant, with mean arterial-to-alveolar Po₂ ratios and oxygenation indices of 0.18 and 12.1 at 6 hours after the second dose of surfactant and 0.31 and 5.9 at 6 hours after the third dose of surfactant, eliminating the need for a fourth dose in any infant in the study group. After three doses of surfactant, persistent pulmonary hypertension had resolved in all but one of the infants in the study group versus none of the infants in the control group. No air leaks developed in any of the 20 infants in the study group after surfactant therapy, and only 1 infant required extracorporeal membrane oxygenation. Air leaks developed in 5 of the 20 infants in the control group, and 6 underwent extracorporeal poreal membrane oxygenation. The duration of mechanical ventilation, oxygen therapy, and admission was significantly shorter in the surfactant group than in the control group.

Conclusion. Surfactant replacement therapy, if started within 6 hours after birth, improves oxygenation and reduces the incidence of air leaks, severity of pulmonary morbidity, and hospitalization time of term infants with MAS.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. A. Engle and and the Committee on Fetus and Newborn Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate Pediatrics, February 1, 2008; 121(2): 419 - 432. [Abstract] [Full Text] [PDF]

				T. P. Stevens and R. A. Sinkin Surfactant Replacement Therapy Chest, May 1, 2007; 131(5): 1577 - 1582. [Abstract] [Full Text] [PDF]

				M. Ghodrat Lung surfactants. Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1504 - 1521. [Abstract] [Full Text] [PDF]

				P. A. Dargaville, B. Copnell, and for the Australian and New Zealand Neonatal Networ The Epidemiology of Meconium Aspiration Syndrome: Incidence, Risk Factors, Therapies, and Outcome Pediatrics, May 1, 2006; 117(5): 1712 - 1721. [Abstract] [Full Text] [PDF]

				K Khambekar, S Nichani, D K Luyt, G Peek, R K Firmin, D J Field, and H C Pandya Developmental outcome in newborn infants treated for acute respiratory failure with extracorporeal membrane oxygenation: present experience Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2006; 91(1): F21 - F25. [Abstract] [Full Text] [PDF]

				O. Flidel-Rimon and E. S. Shinwell Respiratory Distress in the Term and Near-term Infant NeoReviews, June 1, 2005; 6(6): e289 - e297. [Full Text] [PDF]

				B. A. Davidson, P. R Knight, Z. Wang, P. R. Chess, B. A. Holm, T. A. Russo, A. Hutson, and R. H. Notter Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates Am J Physiol Lung Cell Mol Physiol, April 1, 2005; 288(4): L699 - L708. [Abstract] [Full Text] [PDF]

				J. P. Kinsella Meconium Aspiration Syndrome: Is Surfactant Lavage the Answer? Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 413 - 414. [Full Text] [PDF]

				P. A. Dargaville, J. F. Mills, B. M. Headley, Y. Chan, L. Coleman, P. M. Loughnan, and C. J. Morley Therapeutic Lung Lavage in the Piglet Model of Meconium Aspiration Syndrome Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 456 - 463. [Abstract] [Full Text] [PDF]

				P J DAVIS and L S SHEKERDEMIAN Meconium aspiration syndrome and extracorporeal membrane oxygenation Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2001; 84(1): 1F - 3. [Full Text]

				R. ALMAAS, B. ROBERTSON, B. LINDERHOLM, E. LUNDBERG, O. D. SAUGSTAD, and A. MOEN Reversal of Meconium Inhibition of Pulmonary Surfactant by Ferric Chloride, Copper Chloride, and Acetic Acid Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1789 - 1794. [Abstract] [Full Text]

				E. Herting, O. Gefeller, M. Land, L. van Sonderen, K. Harms, B. Robertson, and Members of the Collaborative European Multicenter Surfactant Treatment of Neonates With Respiratory Failure and Group B Streptococcal Infection Pediatrics, November 1, 2000; 106(5): 957 - 964. [Abstract] [Full Text]

				P. Rauprich, O. Moller, G. Walter, E. Herting, and B. Robertson Influence of Modified Natural or Synthetic Surfactant Preparations on Growth of Bacteria Causing Infections in the Neonatal Period Clin. Vaccine Immunol., September 1, 2000; 7(5): 817 - 822. [Abstract] [Full Text] [PDF]

				K. W. LU, H. WILLIAM TAEUSCH, B. ROBERTSON, J. GOERKE, and J. A. CLEMENTS Polymer-Surfactant Treatment of Meconium-induced Acute Lung Injury Am. J. Respir. Crit. Care Med., August 1, 2000; 162(2): 623 - 628. [Abstract] [Full Text] [PDF]

				J M RENNIE and S A BOKHARI Recent advances in neonatology Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1999; 81(1): 1F - 4. [Full Text]

				H. W. TAEUSCH, K. W. LU, J. GOERKE, and J. A. CLEMENTS Nonionic Polymers Reverse Inactivation of Surfactant by Meconium and Other Substances Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1391 - 1395. [Abstract] [Full Text] [PDF]

				B. C. C. Lam, F. FHKCP, and C. Y. Yeung Surfactant Lavage for Meconium Aspiration Syndrome: A Pilot Study Pediatrics, May 1, 1999; 103(5): 1014 - 1018. [Abstract] [Full Text]

				D. Davidson, E. S. Barefield, J. Kattwinkel, G. Dudell, M. Damask, R. Straube, J. Rhines, C.-T. Chang, and the I-NO/PPHN Study Group Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study Pediatrics, March 1, 1998; 101(3): 325 - 334. [Abstract] [Full Text] [PDF]

				T. F. Fok, M. Al-Essa, M. Dolovich, F. Rasid, and H. Kirpalani Nebulisation of surfactants in an animal model of neonatal respiratory distress Arch. Dis. Child. Fetal Neonatal Ed., January 1, 1998; 78(1): 3F - 9. [Abstract] [Full Text]

				G. M. Cleary, M. J. Antunes, D. A. Ciesielka, S. T. Higgins, A. R. Spitzer, and A. Chander Exudative Lung Injury Is Associated With Decreased Levels of Surfactant Proteins in a Rat Model of Meconium Aspiration Pediatrics, December 1, 1997; 100(6): 998 - 1003. [Abstract] [Full Text] [PDF]

				K. J Barrington and N. N Finer Recent advances: care of near term infants with respiratory failure BMJ, November 8, 1997; 315(7117): 1215 - 1218. [Full Text]

				A. J. DAVIS, A. H. JOBE, D. HÄFNER, and M. IKEGAMI Lung Function in Premature Lambs and Rabbits Treated with a Recombinant SP-C Surfactant Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 553 - 559. [Abstract] [Full Text]